tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SYRE Stock Latest News

Spyre Therapeutics Advances in Ulcerative Colitis Treatment Study
Company AnnouncementsSpyre Therapeutics Advances in Ulcerative Colitis Treatment Study
2d ago
SYRE
Spyre Therapeutics Advances Phase 2 Study of SPY072 for Rheumatic Diseases
PremiumCompany Announcements
Spyre Therapeutics Advances Phase 2 Study of SPY072 for Rheumatic Diseases
2d ago
SYRE
Spyre Therapeutics’ SPY002-091 Study: A Potential Game-Changer in Drug Development
PremiumCompany Announcements
Spyre Therapeutics’ SPY002-091 Study: A Potential Game-Changer in Drug Development
2d ago
SYRE
Spyre Therapeutics Advances with Phase 1 Study of SPY003-207
PremiumCompany Announcements
Spyre Therapeutics Advances with Phase 1 Study of SPY003-207
2d ago
SYRE
Spyre Therapeutics Advances with Phase 1 Study of SPY002-072
PremiumCompany Announcements
Spyre Therapeutics Advances with Phase 1 Study of SPY002-072
2d ago
SYRE
Spyre Therapeutics Announces Public Stock Offering
PremiumCompany AnnouncementsSpyre Therapeutics Announces Public Stock Offering
14d ago
8K
SYRE
Spyre Therapeutics 14.86M share Spot Secondary priced at $18.50
Premium
The Fly
Spyre Therapeutics 14.86M share Spot Secondary priced at $18.50
16d ago
SYRE
Spyre Therapeutics announces common stock offering, no amount given
Premium
The Fly
Spyre Therapeutics announces common stock offering, no amount given
16d ago
SYRE
Spyre Therapeutics announces poster presentations at UEGW 2025
PremiumThe Fly
Spyre Therapeutics announces poster presentations at UEGW 2025
24d ago
SYRE
Spyre Therapeutics initiated with a Buy at Deutsche Bank
PremiumThe Fly
Spyre Therapeutics initiated with a Buy at Deutsche Bank
1M ago
SYRE
Promising Developments and Strategic Trials Drive Buy Rating for Spyre Therapeutics
PremiumRatings
Promising Developments and Strategic Trials Drive Buy Rating for Spyre Therapeutics
1M ago
SYRE
Spyre Therapeutics announces first patient dosed in Phase 3 SKYWAY trial
PremiumThe Fly
Spyre Therapeutics announces first patient dosed in Phase 3 SKYWAY trial
1M ago
SYRE
Strategic Growth and Innovation Drive Buy Rating for Spyre Therapeutics
PremiumRatingsStrategic Growth and Innovation Drive Buy Rating for Spyre Therapeutics
2M ago
SYRE
Buy Rating for Spyre Therapeutics: Promising AFFINITY Study Results in Autoimmune Disease Market
Premium
Ratings
Buy Rating for Spyre Therapeutics: Promising AFFINITY Study Results in Autoimmune Disease Market
2M ago
SYRE
Promising Potential of Spyre Therapeutics’ Innovative IBD Treatments Earns Buy Rating
Premium
Ratings
Promising Potential of Spyre Therapeutics’ Innovative IBD Treatments Earns Buy Rating
2M ago
SYRE
Spyre Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Spyre Therapeutics Reports Q2 2025 Financial Results
3M ago
SYRE
Spyre Therapeutics reports Q2 EPS (49c), consensus (71c)
PremiumThe Fly
Spyre Therapeutics reports Q2 EPS (49c), consensus (71c)
3M ago
SYRE
Spyre Therapeutics: A Promising Buy in the IBD Market with Innovative Combination Biologics and Strategic Milestones
PremiumRatings
Spyre Therapeutics: A Promising Buy in the IBD Market with Innovative Combination Biologics and Strategic Milestones
3M ago
SYRE
Positive Phase 2 Data from APGE Bolsters Spyre Therapeutics’ Strategy and Stock Appeal
PremiumRatings
Positive Phase 2 Data from APGE Bolsters Spyre Therapeutics’ Strategy and Stock Appeal
4M ago
SYRE
Spyre Therapeutics: Strategic Execution and Promising Clinical Data Justify Buy Rating
PremiumRatingsSpyre Therapeutics: Strategic Execution and Promising Clinical Data Justify Buy Rating
4M ago
SYRE
Promising Potential and Strategic Growth Justify Buy Rating for Spyre Therapeutics
Premium
Ratings
Promising Potential and Strategic Growth Justify Buy Rating for Spyre Therapeutics
4M ago
SYRE
Buy Rating for Spyre Therapeutics: Promising Monoclonal Antibodies and Strategic Market Positioning
Premium
Ratings
Buy Rating for Spyre Therapeutics: Promising Monoclonal Antibodies and Strategic Market Positioning
4M ago
SYRE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >